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Abstract
Dynamic treatment regimes in oncology and other disease areas often can be char-
acterized by an alternating sequence of treatments or other actions and transition
times between disease states. The sequence of transition states may vary substan-
tially from patient to patient, depending on how the regime plays out, and in practice
there often are many possible counterfactual outcome sequences. For evaluating the
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regimes, the mean final overall time may be expressed as a weighted average of the
means of all possible sums of successive transitions times. A common example arises
in cancer therapies where the transition times between various sequences of treat-
ments, disease remission, disease progression, and death characterize overall survival
time. For the general setting, we propose estimating mean overall outcome time by
assuming a Bayesian nonparametric regression model for the logarithm of each tran-
sition time. A dependent Dirichlet process prior with Gaussian process base measure
(DDP-GP) is assumed, and a joint posterior is obtained by Markov chain Monte Carlo
(MCMC) sampling. We provide general guidelines for constructing a prior using em-
pirical Bayes methods. We compare the proposed approach with inverse probability
of treatment weighting. These comparisons are done by simulation studies of both
single-stage and multi-stage regimes, with treatment assignment depending on base-
line covariates. The method is applied to analyze a dataset arising from a clinical trial
involving multi-stage chemotherapy regimes for acute leukemia. An R program for
implementing the DDP-GP-based Bayesian nonparametric analysis is freely available
at https://www.ma.utexas.edu/users/yxu/.
KEY WORDS: Dependent Dirichlet process; Gaussian process; G-Estimation; In-
verse probability of treatment weighting; Markov chain Monte Carlo.
1 Introduction
We propose a Bayesian nonparametric (BNP) approach for evaluating dynamic treatment
regimes (DTRs) in which the outcome at each stage is a random transition time between
two disease states. The final outcome of primary interest is the sum, T , of a sequence of
transition times. The sequence of transition times that are actually observed is determined
by the way that the patient’s treatment regime plays out. The mean of T may be expressed as
an appropriately weighted average over all possible sequences of event times. For example,
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with fatal diseases T often is overall survival (OS) time. An algorithm commonly used
by oncologists in chemotherapy of solid tumors is to choose the patient’s initial (frontline)
treatment based on his/her baseline covariates, continue as long as the patient’s disease
is stable, switch to a different chemotherapy (salvage) if progressive disease (P ) occurs,
stop chemotherapy if the tumor is brought into complete or partial remission (C), and
begin salvage if P occurs at some time after C. There are many elaborations of this in
oncology, including multiple attempts at salvage therapy, use of consolidation therapy for
patients in remission, suspension of therapy if severe toxicity is observed, or inclusion of
radiation therapy or surgery in the regime. An important potential application of this
structure is treatment regimes for psychological disorders or drug addiction. For example,
in treatment of schizophrenia one may replace P by a psychotic episode or other worsening
of the subject’s psychological status, C by a specified improvement in mental status, and
death by a psychological breakdown severe enough to require hospitalization.
Denote the action at stage ` of the DTR by Z`, which may be a treatment or a decision
to delay or terminate therapy. Here, the term stage refers to the decision points in the
DTR – that is, the choice of frontline and possible salvage therapies. At each stage we
observe some disease state s`, such as P,C or death (D). Let T
j,r denote the transition
time from disease state j to state r, with j = 0 the patient’s initial disease status. See
Figure 1 for an example (details of which will be provided later) with up to nstage = 3
stages, nstate = 4 disease states, and a total of nT = 7 possible transition times. The
actual number of stages and observed transition times varies across patients and depends on
the specific treatment-outcome sequence. A DTR is the sequence Z = (Z1, Z2, · · · ), where
each Z` is an adaptive action based on the patient’s history H`−1 of previous treatments
and transition times, and H0 refers to baseline covariates. One possible treatment-outcome
sequence is (H0, Z1, T 0,P , Z2, T P,D), in which the initial chemotherapy Z1 was chosen based
onH0, Z2 was chosen based onH1 = (H0, Z1, T 0,P ) and given at time T 0,P of P , and OS time
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Figure 1: The scheme
T = T 0,P + T P,D. Similarly, a patient brought into remission who later suffers progressive
disease has sequence (H0, Z1, T 0,C , TC,P , Z2, T P,D) and T = T 0,C+TC,P +T P,D. We will focus
on application of BNP methods for estimating the conditional distributions of the transition
times give the most recent histories, with the goal to estimate the mean of T for each possible
DTR. Key elements of our proposed approach are quantification of all sources of uncertainty
and prediction of T under a reasonable set of viable counterfactual DTRs (Wang et al., 2012).
BNP methods have been used in estimating regime effects by Hill (2011) and Karabatsos
and Walker (2012).
Since all elements of a DTR may affect T , the clinically relevant problem is optimizing the
entire regime, rather than the treatment at one particular stage. Most clinical trials or data
analyses attempt to reduce variability by focusing on one stage of the actual DTR, usually
frontline or first salvage treatment, or by combining stages in some manner. This often
misrepresents actual clinical practice, and consequently conclusions may be very misleading.
For example, an aggressive frontline cancer chemotherapy may maximize the probability of C,
but it may cause so much immunologic damage that any salvage treatment given after rapid
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relapse, i.e. short TC,P , may be unlikely to achieve a second remission. In contrast, a milder
induction treatment may be suboptimal to eradicate the tumor, but it may debulk the tumor
sufficiently to facilitate surgical resection. Such synergies may have profound implications
for clinical practice, especially because effects of multi-stage treatment regimes often are not
obvious and may seem counter-intuitive. Physicians who have not been provided with an
evaluation of the composite effects of entire regimes on the final outcome may unknowingly
set patients on pathways that include only inferior regimes.
A major practical advantage of BNP models is that they often provide better fits to com-
plicated data structures than can be obtained using parametric model-based methods. In our
motivating application, where leukemia patients were randomized among initial chemother-
apy treatments but not among later salvage therapies, the BNP model provides good fits
for each transition time distribution conditional on previous history. Failure to randomize
patients in treatment stages after the first is typical in clinical trials, most of which ignore
all but the first stage of therapy. In contrast, sequential multi-arm randomized treatment
(SMART) designs, wherein patients are re-randomized at stages after the first, have been
used in oncology trials (Thall et al., 2000, 2007a,b), and are being used increasingly in trials
to study multi-stage adaptive regimes for behavioral or psychological disorders (Dawson and
Lavori, 2004; Murphy et al., 2007a,b; Connolly and Bernstein, 2007).
While re-randomization is desirable, it is not commonly done and inference has to adjust
for this lack of randomization. A wide array of methods have been proposed for evaluating
DTRs from observational data and longitudinal studies, beginning with the seminal papers
by Robins (1986, 1987, 1989, 1997) on G-estimation of structural nested models. Additional
references include applications to longitudinal data in AIDS (Herna´n et al., 2000), inverse
probability of treatment weighted (IPTW) estimation of marginal structural models (Murphy
et al., 2001; van der Laan and Petersen, 2007; Robins et al., 2008), G-estimation for optimal
DTRs (Murphy, 2003; Robins, 2004), and a review by Moodie et al. (2007). A variety of
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methods have been developed to evaluate DTRs from clinical trials (Lavori and Dawson,
2000; Thall et al., 2002; Murphy, 2005). For survival analysis, Lunceford et al. (2002)
introduced ad hoc estimators for the survival distribution and mean restricted survival time
under different treatment policies. These estimators, although consistent, were inefficient
and did not exploit information from auxiliary covariates. Wahed and Tsiatis (2006) derived
more efficient, easy-to-compute estimators that included auxiliary covariates for the survival
distribution and related quantities of DTRs. Their estimators compared DTRs using data
from a two-stage randomized trial, in which two options were available for both stages and
the second-stage treatment assignments were determined by randomization. However, these
estimators must be adapted for more general or more complicated designs that permit various
numbers of treatment options at each stage and involve the scenarios where second-stage
treatment is not randomized, but rather determined by the attending physicians.
In settings where the DTR’s final overall time, such as survival time, is the sum of a
sequence of transition times, we propose a Bayesian nonparametric approach that employs
a nonparametric regression model for (the logarithm of) each transition time conditional
on the most recent history of actions and outcomes. We assume a dependent Dirichlet
process prior with Gaussian process base measure (DDP-GP), and compute a joint posterior
by Markov chain Monte Carlo (MCMC) sampling. To address the important issue that
Bayesian analyses depend on prior assumptions, we provide guidelines for using empirical
Bayes methods to establish prior hyperparameters. Posterior analyses include estimation of
posterior mean overall outcome times and credible intervals for each DTR.
The rest of the paper is organized as follows. In Section 2 we review the motivating
study, and give a brief review of DTRs in settings with successive transition times in Section
3. We present the DDP-GP model in Section 4. A simulation study of the BNP approach in
single-stage and multi-stage regimes, with comparison to frequentist IPTW, is summarized in
Section 5. We re-analyze the leukemia trial data in Section 6, and close with brief discussion
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in Section 7.
2 Motivating Study
Our proposed methodology is motivated by a clinical trial conducted at The University of
Texas M.D. Anderson Cancer Center to evaluate chemotherapies for acute myelogenous
leukemia (AML) or myelo-dysplastic syndrome (MDS). Patients were randomized fairly
among four front-line combination chemotherapies for remission induction: fludarabine +
cytosine arabinoside (ara-C) plus idarubicin (FAI), FAI + all-trans-retinoic acid (ATRA),
FAI + granulocyte colony stimulating factor (GCSF), and FAI + ATRA + GCSF. The goal
of induction therapy for AML/MDS is to achieve complete remission (C), a necessary but not
sufficient condition for long-term survival. Patients who do not achieve C, or who achieve C
but later relapse, are given salvage treatments as another attempt to achieve C. Following
conventional clinical practice, patients were not randomized among salvage therapies, which
were chosen by the attending physicians based on clinical judgment. Since there were many
types of salvage, these are broadly classified into two categories as either containing high
dose ara-C (HDAC) or not. This data set was analyzed initially using conventional methods
(Estey et al., 1999), including logistic regression, Kaplan-Meier estimates, and Cox model
regression, including comparisons of the induction therapies in terms of OS that ignored
possible effects of salvage therapies.
Figure 1 illustrates the actual possible therapeutic pathways and outcomes of the patients
during the trial, which is typical of chemotherapy for AML/MDS. Death might occur (1)
during induction therapy, (2) following salvage therapy if the disease was resistant to induc-
tion, (3) during C, or (4) following disease progression after C. Wahed and Thall (2013)
re-analyzed the data from this trial by accounting for the structure in Figure 1, and identi-
fied 16 DTRs including both frontline and salvage therapies. To correct for bias due to the
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lack of randomization in estimating the mean OS times, they used both IPTW (Robins and
Rotnitzky, 1992) and G-estimation based on a frequentist likelihood. In the G-estimation,
for each transition time they first fit accelerated failure time (AFT) regression models us-
ing Weibull, exponential, log-logistic or log-normal distributions, and chose the distribution
having smallest Bayes information criterion (BIC). They then performed likelihood-based
G-estimation by first fitting each conditional transition time distribution regressed on pa-
tient baseline covariates and previous transition times, and then averaging over the empirical
covariate distribution.
Like Wahed and Thall, the primary goal of our analyses of the AML/MDS dataset is
to estimate mean OS and determine the optimal regime. We build on their approach by
replacing the parametric AFT models for transition times with the DDP-GP model. We
also demonstrate the usefulness of the BNP regression model for G-estimation in simulation
studies of single-stage and multi-stage regimes in which treatment assignments depend on
patient covariates.
3 Dynamic Regimes with Stochastic Transition Times
Denote the set of possible disease states by {0, 1, · · · , nstate}, with 0 denoting the patient’s
initial state before receiving the first treatment. The pairs of states (s`−1, s`) for which a
transition s`−1 → s` is possible at stage ` of the patient’s therapy depend on the particular
regime. Here s0 refers to the patient’s initial state, before start of therapy. We will identify
specific states using letters such as P , C, etc., as in the earlier examples, to replace the
generic integers. For example, in cancer therapy, s`−1 → C means that a patient’s disease
has responded to treatment, P → D means a patient with progressive disease has died, and
of course D → s` is impossible. We denote the transition time from state s`−1 to state
s` in stage ` of treatment by T
`,(s`−1,s`), for ` = 1, · · · , nstage, the maximum number of
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stages in the DTR. When no ambiguity arises we simply write T r,s for the transition time
from state r to s. To simplify notation for the transition time distributions, we denote
the history of all covariates, treatments, and previous transition times through ` stages,
before observation of T `,(s`−1,s`) but including the stage ` action Z` by x` = (H`−1, Z`) =
(x0, Z1, T 1,(s0,s1), · · · , Z`), with x0 = H0. Thus, a DTR is Z = (Z1, Z2, . . .), a sequence of
actions for all possible stages. When no meaning is lost, we will write T `,(s`−1,s`) as T k, where
k = 1, . . . , nT is a running index of all possible state transitions. For example, in Figure 1
we have up to nstage = 3 stages and nT = 7 possible transitions. Similarly, we will write
xk for the corresponding covariate vector. Our use of a single index to identify stage is a
slight abuse of notation since, for example, the actual second stage of therapy might differ
depending on the sequence of outcomes. For example, stage 2 treatment Z2 of a patient with
sequence (x0, Z1, T 1,(0,R), Z2) is first salvage for resistant disease during induction with Z1,
while stage 3 treatment Z3 of a patient with sequence (x0, Z1, T 1,(0,C), T 2,(C,P ), Z3) is first
salvage for progressive disease after achieving response initially with Z1. This latter example
could be elaborated if, under a different regime, consolidation therapy, Z2, were given for
patients who enter C, in which case the sequence would be (x0, Z1, T 1,(0,C), Z2, T 2,(C,P ), Z3).
Below we will develop a general BNP model for all possible conditional distributions
of the form p(T k | xk) = p(T `,(s`−1,s`) | x`). This determines the likelihood for all possible
sequences of treatments and transition times through nT transitions as the product
L =
nT∏
k=1
p(T k | xk). (1)
The overall time for any counterfactual sequence of transition times is the sum T =∑nT
k=1 T
k. Our goal is to estimate the mean of T for each possible Z.
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4 A Nonparametric Bayesian Model for DTR’s
4.1 DDP and Gaussian Process Prior
To specify the BNP model, we denote Y k = log(T k) and write the distribution of [Y k | xk] as
F k(· | xk). For convenience, we will refer to xk as ‘covariates’. We construct a BNP survival
regression model for each F k(· | xk) by successive elaborations, starting with a model for
a discrete random distribution G(·). We then use a Gaussian kernel to extend this to a
prior for a continuous random distribution F (·), and finally endow the kernel means with a
regression structure by expressing them as functions of xk. The latter construction extends F
to a family {F (· | xk)}, indexed by xk. The construction of G(·) and F (·) is briefly outlined
below, by way of a brief review of BNP models. In the end we will only use the last model
{F (· | xk)}, which we use as sampling model for Y k. See, for example, Mu¨ller and Mitra
(2013) and Mu¨ller and Rodriguez (2013) for more extensive reviews of BNP inference.
The Dirichlet process (DP) prior first was proposed by Ferguson (1973) as a probability
distribution on a measurable space of probability measures. The DP is indexed by two
hyperparameters, a base measure, G0, and a precision parameter, α > 0. If a random
distribution G follows a DP prior, we denote this by G ∼ DP (α,G0). Denoting a beta
distribution by Be(a, b), if G ∼ DP (α,G0) then G(A) ∼ Be{αG0(A), α[1−G0(A)]} for any
measurable set A, and in particular E{G(A)} = G0(A). Let δ(θ) denote a point mass at θ.
Sethuraman (1991) provided a useful representation of the DP as G =
∑∞
h=0whδ(θh), where
θh
i.i.d.∼ G0, and the weights wh are generated sequentially from rescaled Beta distributions
as wh/(1 −
∑h−1
r=1 wr) ∼ Be(1, α), the so-called “stick-breaking” construction. The discrete
nature of G is awkward in many applications. A DP mixture model extends the DP model
by replacing each point mass δ(θh) with a continuous kernel centered at θh. Without loss
of generality, we will use a normal kernel. Let N(·; µ, σ) denote the measure of a normal
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distribution with mean µ and standard deviation (sd) σ. The DP mixture model assumes
G =
∞∑
h=0
whN(· ; θh, σ). (2)
The use and interpretation of (2) is very similar to that of a finite mixture of normal models.
In practical applications, the sum in (2) is often truncated at a reasonable finite value. This
model is useful for density estimation under i.i.d. sampling from an unknown distribution,
and it provides good fits to a wide variety of datasets because a mixture of normals can
closely approximate virtually any distribution (Ishwaran and James, 2001).
To include the regression on covariates that we will need for the survival model of each
conditional transition time distribution, (Y k | xk), we extend the DP mixture to a dependent
DP (DDP), which was first proposed by MacEachern (1999). The basic idea of a DDP is to
endow each θkh with additional structure that specifies how it varies as a function of covariates
xk. Writing this regression function as θkh(x
k) for each summand in (2), and returning to the
conditional transition time distributions, we assume that
F k(y | xk) =
∞∑
h=0
wkhN(y; θ
k
h(x
k), σk). (3)
This form of the DDP, which includes both the convolution with a normal kernel and func-
tional dependence on covariates, provides a very flexible regression model.
To complete our specification of the DDP, we will assume that the θkh(·)’s are independent
realizations from a Gaussian process prior. The Gaussian process first was popularized by
O’Hagan and Kingman (1978) in Bayesian inference for a random function (unrelated to the
use in a DDP prior). For more recent discussions see, for example, Rasmussen and Williams
(2006); Neal (1995); Shi et al. (2007). Temporarily suppressing the transition index k and
running index h in (3), and denoting x = (x1, · · · , xn), a Gaussian process is a stochastic
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process θ(·) in which θ(x) = {θ(x1), . . . , θ(xn)}′ has a multivariate normal distribution with
mean vector µ(x) = (µ(x1), . . . , µ(xn)) and (n × n) covariance matrix C(x) for x of any
dimension n ≥ 1. We denote this by θ ∼ GP (µ,C).
We use the GP prior to define the dependence of θkh(x
k) as a function of xk by assuming
{θkh(xk)} ∼ GP (µkh, Ck), as a function of xk, for fixed h. We will refer to the DDP with a
convolution using a normal kernel and a Gaussian process prior on the normal kernel means as
a DDP-GP model. While the mean and covariance processes of the GP can be quite general,
in practice, Ck(xk) often is parameterized as a function Ckij = C(x
k
i , x
k
j ; ξ
k), where ξk is a
vector of hyperparameters, and the mean function is indexed similarly by hyperparameters
βkh and written as µ
k
h(x
k | βkh). In the DTR setting, since each covariate vector xk is a
history, its entries can include baseline covariates, transition times, and indicators of previous
treatments or actions. To obtain numerically reasonable parameterizations of the Gaussian
process functions Ck and µkh, we standardize numerical-valued covariates such as age. We
now have
{θkh(xk)} ∼ GP (µkh(xk), Ck(xk)), h = 1, 2, ...
To specify the form of µkh and C
k, let i = 1, 2, · · · , index patients, so that xki is the history of
patient i at transition k, and define the indicator δij = I(i = j) = 1 if i = j and 0 otherwise.
We model the mean function µkh(·) as a linear regression, by assuming that
µkh(x
k
i ) = x
k
iβ
k
h. (4)
For patients i and j, we assume that the covariance process takes the form
Ck(xki ,x
k
j ) = exp{−
Mk∑
m=1
(xkim − xkjm)2}+ δijJ2, i, j = 1, . . . , n, (5)
where Mk is the number of covariates at transition k and J is the variance on the diagonal
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reflecting the amount of jitter (Bernardo et al., 1999), which usually takes a small value (e.g,
J = 0.1). For binary covariates, the quadratic form in (5) reduces to counting the number of
binary covariates in which two patients differ. If desired, additional hyperparameters could
be introduced in (5) to obtain more flexible covariance functions. However, in practice this
form of the covariance matrix yields a strong correlation for observations on patients with
very similar xk, and has been adopted widely (Williams, 1998).
Combining all of these structures, we denote the model for conditional distribution of the
kth transition time as
F k ∼ DDP-GP{{µkh}, Ck;αk, {βkh}, σk} , (6)
recalling that the weights of the DDP are generated sequentially as wkh/(1 −
∑h−1
r=1 w
k
r ) ∼
Be(1, αk). For later reference we state the full model,
p(yki | xki , F k) = F k(yki | xki )
F k ∼ DDP-GP{{µkh}, Ck;αk, {βkh}, σk} (7)
k = 1, . . . , nT .
4.2 Determining Prior Hyperparameters
As priors for βkh in (4) we assume β
k
h ∼ N(βk0 ,Σk0) for each transition k, h = 1, 2, . . . . For the
normal pdfs of the DDP mixture models we assume the precision parameters follow the same
prior (σk)−2 i.i.d.∼ Ga(λ1, λ2) and, similarly, for the parameters that determine the weights
of the DDP mixture under the stick-breaking construction we assume αk
i.i.d.∼ Ga(λ3, λ4).
To apply the DDP-GP model, one must first determine numerical values for the fixed
hyperparameters {βk0 , Σk0, k = 1, 2, ...} and λ = (λ1, λ2, λ3, λ4). This is a critical step. These
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numerical hyperparameter values must facilitate posterior computation, and they should not
introduce inappropriate information into the prior that would invalidate posterior inferences.
With this in mind, the hyperparameters (βk0 ,Σ
k
0) for the k
th transition time covariate effect
distribution may be obtained via empirical Bayes by doing a preliminary fits of a lognormal
distribution Y k = log(T k) ∼ N(xkβk0 , σk0) for each transition k. The covariate effect estimates
then can be used as the values of βk0 . Similarly, we assume a diagonal matrix for Σ
k
0 with the
diagonal values also obtained from the preliminary fit of the lognormal distribution. Once
an empirical estimate of σk is obtained, one can tune (λ1, λ2) so that the prior mean of σ
k
equals the empirical estimate and the variance equals 1 or a suitably large value to ensure a
vague prior. In contrast, information about αk typically is not available in practice, and an
empirical Bayes approach cannot be applied to determine (λ3, λ4). However, setting λ3 = λ4
= 1 gives a Gamma(1, 1) distribution, which has mean 1 and variance 1, and is a well
behaved, noninformative prior for αk that may be used generally when fitting the DDP-GP
model.
This approach works in practice because the parameter βk0 specifies the prior mean for
the mean function of the GP prior, which in turn formalizes the regression of T k on the
covariates xk, including treatment selection. The imputed treatment effects hinge on the
predictive distribution under that regression. Excessive prior shrinkage could smooth away
the treatment effect that is the main focus. The use of an empirical Bayes type prior in
the present setting is similar to empirical Bayes priors in hierarchical models. This type
of empirical Bayes approach for hyperparameter selection is commonly used when a full
prior elicitation is either not possible or is impractical. Inference is not sensitive to values
of the hyperparameters λ that determine the priors of σk and αk for two reasons. First,
the standard deviation σk is the scale of the kernel that is used to smooth the discrete
random probability measure generated by the DDP prior. It is important for reporting a
smooth fit, that is for display, but it is not critical for the imputed fits in our regression
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setting. Assuming some regularity of the posterior mean function, smoothing adds only
minor corrections. Second, the total mass parameter αk determines the number of unique
clusters formed in the underlying Polya urn. Because most clusters are small a priori,
including many singleton clusters, varying the number of these clusters by changing the
prior of αk does not significantly change the posterior predictive values that are the basis for
the proposed inference.
The conjugacy of the implied multivariate normal on {θkh(xk), h = 0, 1, . . . } and the
normal kernel in (3) greatly simplify the computations, since any Markov chain Monte Carlo
(MCMC) scheme for DP mixture models can be used. MacEachern and Mu¨ller (1998) and
Neal (2000) described specific algorithms to implement posterior MCMC simulation in DPM
models. Ishwaran and James (2001) developed alternative computational algorithms based
on finite DPs, which truncated (2) after a finite number of terms. We provide details of
MCMC computations in the online supplement.
5 Simulation Studies
We conducted three simulation studies to evaluate the performance of the proposed DDP-
GP model as a tool for estimating the mean of T in survival regression settings. The studies
focused, respectively, on estimation of (i) survival regression; (ii) regime effects in a study
with two treatment arms and single-stage regimes; and (iii) regime effects in a study with
eight multi-stage regimes. For each of the latter two studies, the treatment assignment
probabilities depend on patient covariates. That is, we introduce a treatment selection bias.
In all three simulations, we implement inference under DDP-GP models. In (i) we use a
single survival regression F (Yi | xi) for a patient-specific baseline covariate vector xi. For
(ii) we still use a single DDP-GP model F (Yi | xi, Zi), now adding a treatment indicator
Zi to the survival regression. In (iii) we use independent DDP-GP models F
k(Y ki | xki )
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for multiple transition times, k = 1, . . . , nT , similar to the motivating application. For all
three simulation studies, the hyperprior parameters were determined using the empirical
Bayes approach described earlier. For all posterior computations, the MCMC algorithm
was implemented with an initial burn-in of 2,000 iterations and a total of 5,000 iterations,
thinning out in batches of 10. This worked well in all cases, with convergence diagnostics
using the R package coda showing no evidence of practical convergence problems. Traceplots
and empirical autocorrelation plots (not shown) for the imputed parameters indicated a well
mixing Markov chain.
5.1 Survival Time Regression
The first simulation was designed to study the DDP-GP regression model by comparing
inference for a survival function with the simulation truth. In this study, we did not evaluate
a regime effect, but rather focused on inference for the survival curve.
For each subject, we generated T = survival time, the covariates x1 = tumor size
(0=small, 1=large) and x2 = body weight, and x3 = a biomarker (0=absent, 1=present).
We assumed that small and large tumor sizes each had probability .50. Body weights were
computed by sampling from a uniform distribution, Unif(80, 150), with the covariate x2
defined by shifting and scaling to obtain mean 0 and variance 1. The biomarker was asso-
ciated with tumor size, as follows. Patients in the large tumor size group were biomarker
negative with probability 0.7 and biomarker positive with probability 0.3. Patients with
small tumor size were biomarker negative with probability 0.3 and biomarker positive with
probability 0.7. Let Y ∼ LN(m, s) denote a log normal random variable Y = log T for
T ∼ N(m, s). By a slight abuse of notation, we also use LN(m, s) to denote the log
normal p.d.f. Let xi = (1, xi,1, xi,2, xi,3) denote the covariates for patient i. We simu-
lated each sample Y1, · · · , Yn of n observations from a mixture of lognormal distributions,
Yi|xi ∼ 0.4 LN(xiβ1, σ2) + 0.6 LN(xiβ2, σ2), where the true covariate parameters of the
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mixture components were β1 = (1, 2,−2, 1)′ and β2 = (2,−1, 3,−3)′, with σ2 = 0.4. For
comparison, we also fit an AFT regression model, assuming
Yi = log(Ti) = x
′
iβ + σi, i = 1, . . . , n
with i following an extreme value distribution, so that Ti follows a Weibull distribution.
In this simulation, we considered four scenarios, with n = 50, 100, or 200 observations
without censoring or n = 200 with 23% censoring. For each scenario, N = 1, 000 trials were
simulated. For each simulated data set we fit a DDP-GP survival regression model F (Yi | xi).
For simulation j, let S(t | x) = p(Tn+1 ≥ t | xn+1,j = x, data) denote the posterior expected
survival function for a future patient with covariate x. Using the empirical distribution
1
n
∑n
i=1 δxij to marginalize w.r.t. xn+1,j and averaging across simulations, we get
S(t) =
1
N
N∑
j=1
1
n
n∑
i=1
S(t | xij).
Figure 2 compares S(·) under the DDP-GP model with the simulation truth
S0(t) =
1
N
N∑
j=1
1
n
n∑
i=1
S0(t | xij),
and a maximum likelihood estimate (MLE) under a Weibull AFT model. In each scenario,
the true curve is given as a solid black solid line, the MLE of the survival functions under the
AFT regression model assuming a Weibull distribution as a solid green solid line, and the
posterior mean survival function under the DDP-GP model as a solid red line with point-wise
90% credible bands as two dotted red lines.
In all four scenarios, the DDP-GP model based estimate reliably recovered the shape of
the true survival function and avoided the excessive bias seen with the Weibull MLE. As
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Figure 2: Simulation example 1. True mean survival functions (black color) and estimated mean
survival functions under the DDP-GP model (red color) for sample sizes n = 50, 100, 200 and
n = 200 with 23% censoring for 1,000 simulations. For comparisons, we also show the MLE under
an AFT regression with Weibull distribution (green color). In all cases, the point-wise 90% credible
bands are also displayed as the region between two dotted red lines.
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expected, the three scenarios without censoring show that increasing sample size gives more
accurate estimation. With 23% censoring, the DDP-GP estimate becomes less accurate, but
it still is much closer to the simulation truth than the Weibull MLE.
5.2 Estimating a Treatment Effect in Single-stage Regimes
The second simulation study was designed to investigate inference under the DDP-GP model
for a regime effect in a single-stage treatment setting. The simulated data represent what
might be obtained in an observational setting where treatment is chosen by the attending
physician based on patient covariates, rather than from a fairly randomized clinical trial. We
simulated a binary treatment indicator Zi ∈ {0=control, 1=experimental} that depended on
two continuous covariates, xi = (Li,Wi), for n = 100 patients, i = 1, . . . , n. For example, Li
could be a patient’s creatinine to quantify kidney function, and Wi could be body weight.
We generated Li from a mixture of normals, Li ∼ 12N(40, 102) + 12N(20, 102), which could
correspond to a subgroup of patients having worse kidney function (higher creatinine level)
due to damage from prior chemotherapy. We assumed that Wi ∼ Unif(−
√
12,
√
12), a
uniform with zero mean and unit standard deviation, as could arise from standardizing a
uniformly distributed raw variable. We generated the treatment indicators using the modified
logistic regression model
p(Zi = 1 | Li,Wi) =

0.05 if {1 + exp[−2(Li − 30)/10]}−1 ≤ 0.05
0.95 if {1 + exp[−2(Li − 30)/10]}−1 ≥ 0.95
{1 + exp[−2(Li − 30)/10]}−1 otherwise,
that is, a logistic regression with intercept 30 and slope 1/5 truncated at 0.05 and 0.95. This
produces a very unbalanced treatment assignment, for example, p(Zi = 1 | Li = 40) = 0.88
versus p(Zi = 1 | Li = 20) = 0.12. This could arise in a setting where standard therapy,
Z = 0, is known to be nephrotoxic, while it is believed by most of the treating physicians
that the experimental therapy, Zi = 1, is not, so patients with high creatinine are more likely
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to be given the experimental therapy. In this simulation study, the goal is to estimate the
comparative effect on survival of the experimental therapy versus the control. In the two
treatment arms, we generated patients’ responses from
Y (1) ∼ 1
2
N(3− 0.2L+
√
L− 0.1W, σ) + 1
2
N(2− 0.2L+
√
L− 0.1W, σ)
and
Y (0) ∼ N(−0.2L+
√
L− 0.1W, σ),
with σ = 0.4. We simulated 1,000 trials. Note that under the simulation truth the treatment
effect, E[Y (1)− Y (0) | x = (L,W )] = 2.5, is constant across L,W .
Figure 3(a) plots the simulation truth for the mean response curve under Z = 1 and
Z = 0 versus L, with W ≡ 0, in one randomly selected trial. The upper red solid curve
represents E[Y (1) | L,W = 0] and the lower black curve represents E[Y (0) | L,W = 0].
The red dots close to the upper curve are the observations for experimental arm patients
and the black dots close to the lower curve are the observations for the control arm patients.
We define an average treatment effect for the entire population under the simulation truth
as 1
n
∑n
i=1E[Yi(1)− Yi(0)] = 2.5.
We implemented inference for a survival regression F (Yi | xi, Zi) using the proposed
DDP-GP model. Figure 3(b) summarizes inference for the data from panel (a). Let Yˆi(z) =
E(Yn+1 | Ln+1 = Li,Wn+1 = Wi, Zi = z, data) denote the posterior expected response for a
future patient n+1. We define an estimated average treatment effect as 1
n
∑n
i=1[Yˆi(1)−Yˆi(0)].
Figure 3(b) shows the estimated average treatment effect (horizontal red line), and credible
intervals for individual effects Yˆi(1)− Yˆi(0) (vertical line segments, located at Li).
For comparison, we also applied both linear regression (LR) and an IPTW method to the
simulated data to estimate the average treatment effect. The LR method fits observations
from both treatments using linear predictor functions and estimates the average treatment
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Figure 3: Simulation example 2. (a) Simulated data for one (treatment, control) pair. The upper
red solid curve represents E[Y (1) | X], the lower black curve represents E[Y (0) | X] given W = 0.
The red dots close to the upper curve are the treated observations and the black dots close to
the lower curve are the untreated. (b) Average treatment effect estimations. The black solid line
represents the true average treatment effect, the red line represents posterior mean treatment effect
estimates under the DDP-GP model, turquoise blue represents IPTW estimate, the heliotrope line
represents the linear regression estimate. The vertical line segments are marginal 90% posterior
intervals for the treatment effect at each L value from treated observations.
effect, assuming Yi(1) = β10 + β11Li + β12Wi + 1i and Yi(0) = β00 + β01Li + β02Wi + 0i.
Denoting the least squares estimates by βˆzj for z = 0, 1 and j = 0, 1, 2, the estimated means
are Eˆ{Yi(z)} = βˆz0 + βˆz1Li + βˆz2Wi. We define an estimated average treatment effect as
1
n
∑
i [Eˆ{Yi(1)} − Eˆ{Yi(0)}]. The IPTW method assigns each patient i a weight bi equal
to the inverse of an estimate of p(Zi | xi), the conditional probability of receiving his or
her actual treatment (Robins et al., 2000), with the estimate obtained by fitting a logistic
regression model. The effect of weighting is to create a pseudo-population consisting of
bi copies of each patient i. For example, if bi = 5 then five copies of the i
th patient are
contributed to the pseudo-population. Thus, for z = 0 or 1, we define an estimated mean
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outcome
IPTW(Z = z) =
∑
i I(Zi = z)biYi∑
i I(Zi = z)bi
,
and a corresponding average treatment effect estimate IPTW(Z = 1) − IPTW(Z = 0).
The DDP-GP point estimate of the average effect of the treatment is the posterior mean
2.31 with 90% posterior credible interval (1.89, 2.96). The LR fit yields an overestimate,
4.13, while IPTW yields an underestimate, 1.11. In Figure 3(b), the red horizontal line
represents the posterior mean treatment effect estimate obtained from the DDP-GP model.
The short horizontal black, turquoise blue and heliotrope solid lines represent the true average
treatment effect, IPTW estimate, and LR estimate, respectively. The vertical green and
blue segments are marginal 90% posterior credible intervals for the treatment effect at each
L value from treated observations. Lengths of posterior credible intervals larger than 2 are
highlighted by blue segments. Note that the uncertainty bounds grow wider in the range
where there is less overlap across treatment groups, that is, over a range of covariate values for
which we do not observe reliable empirical counterfactuals for each data point (e.g. L > 50).
Most of the credible intervals reasonably cover the true treatment effect.
Figure 3 reports inference for one hypothetical data set. For a more meaningful com-
parison we carried out extensive simulation and report the distribution of estimated regime
effects across repeat simulations. We compared the regime effects estimates obtained by
DDP-GP, IPTW, and LR based on data from 1,000 simulated trials. Figure 4 gives density
plots of the estimated regime effects. Compared to the estimates obtained from DDP-GP,
the IPTW estimates are much more variable, ranging from 1.14 to 7.13. In general, the
LR estimates are highly biased, and overestimate the true effects. The distribution of esti-
mated regime effects under the DDP-GP model is remarkably narrowly centered around the
simulation truth, in comparison with the two alternative methods.
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Figure 4: The density plot of estimated regime effects by DDP-GP, IPTW and linear regres-
sion in 1,000 trials.
5.3 Regime Effect for Multi-stage Regimes
Our third simulation study was designed to examine inference on strategy effects for multi-
stage regimes. This simulation is a stylized version of the leukemia data that we will analyze
in Section 6. We simulated samples of size n = 200. Patients initially were randomized
between two induction therapies, with the randomization probabilities based on their blood
glucose values, which were simulated as Li ∼ N(100, 102). Denoting Z1 ∈ {a1, a2}, if
Li < 100, then Z
1
i = a1 with probability 0.6 and Z
1
i = a2 with probability 0.4. If Li ≥ 100,
then Z1i = a1 with probability 0.4 and Z
1
i = a2 with probability 0.6. We then generated
a response (see below). For patients who were resistant (R) to their induction therapies,
they were assigned salvage treatment Z2,1 ∈ {b11, b12}. If their blood glucoses were smaller
than 100, Z2,1 = b11 with probability 0.8 and Z
2,1 = b12 with probability 0.2; if their blood
glucoses were larger than 100, Z2,1 = b11 with probability 0.2 and Z
2,1 = b12 with probability
0.8. Patients who achieved C and subsequently suffered disease progression (P ), were given
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salvage treatment Z2,2 ∈ {b21, b22}. The salvage treatment for each patient Z2,2i was assigned
based on his/her baseline covariate Li: if Li < 100, Z
2,2
i = b21 with probability 0.2 and
Z2,2i = b22 with probability 0.8; if Li ≥ 100, Z2,2i = b21 with probability 0.85 and Z2,2i = b22
with probability 0.15. Thus, the survival time for each patient was evaluated as
Ti =
 T
(0,R)
i + T
(R,D)
i if patient i had sequence (L,Z
1, T (0,R), Z2,1)
T
(0,C)
i + T
(C,P )
i + T
(P,D)
i if patient i had sequence (L,Z
1, T (0,C), T (C,P ), Z2,2).
We simulated the times of two completing risks R and C as T
(0,R)
i ∼ LN(β(0,R)x(0,R)i , σ(0,R))
and T
(0,C)
i ∼ LN(β(0,C)x(0,C)i , σ(0,C)), where β(0,R) = (2, 0.02, 0), β(0,C) = (1.5, 0.03, −0.8),
with xki = (1, Li, Z
1
i ) for k ∈ {(0, R), (0, C)}. For transitions k ∈ {(R,D), (C,P ), (P,D)}, we
generated transition times T ki ∼ LN(βkxki , σk), where β(R,D) = (−0.5, 0.03, 0.2, 0.5, 0.3),
β(C,P ) = (1, 0.05, 1, −0.6), β(P,D) = (0.8, 0.04, 1.5, −1, 0.5, 0.5), with covariate vectors
x
(R,D)
i = (1, Li, Z
1
i , log(T
(0,R)
i ), Z
2,1
i ), x
(C,P )
i = (1, Li, Z
1
i , log(T
(0,C)
i )) and x
(P,D)
i = (1, Li, Z
1
i ,
log(T
(0,C)
i ), log(T
(C,P )
i ), Z
2,2
i ). We simulated N = 1,000 trials with 15% censoring.
The goal is to estimate mean survival time for each DTR (Z1, Z2,1, Z2,2). We have 8 pos-
sible DTRs in this simulation. We applied both inference under the Bayesian nonparametric
DDP-GP model and IPTW to the each simulated dataset to estimate mean survival for each
of the eight possible DTRs. For the nonparametric Bayesian inference we defined indepen-
dent DDP-GP models F k(Y ki | xki ) for each of the nT = 5 log transition times Y ki = log T ki .
Figure 5 gives comparisons of the mean survival estimates using boxplots of (Estimated mean
survival - Simulation truth), based on the simulation sample of 1000 datasets, obtained by
DDP-GP and IPTW, for each possible DTR. The yellow boxplots represent the DDP-GP
posterior mean estimates and the green boxplots represent the IPTW estimators. Figure 5
shows that the DDP-GP estimates on average are much closer to the truth and have much
smaller variability, compared to the IPTW estimates, across all eight scenarios.
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Figure 5: Simulation 3. Small (yellow) boxplots show posterior estimated OS under each
of the 8 regimes as a difference with the simulation truth over 1,000 simulations. The large
(green) boxes show inference under the IPTW approach. In each notched box-whisker plot,
the box shows the interquartile range (IQR) from 1st quantile (Q1) to 3rd quantile (Q3), and
the mid-line is the median. The top whisker denotes Q3+1.5∗IQR and the bottom whisker
Q1-1.5∗IQR. The notch displays a confidence interval for the median, that is median±1.57 ∗
IQR/
√
n. Here n = 1000.
6 Evaluation of the Leukemia Trial Regimes
6.1 Computing Mean Survival Time
We first review the likelihood used by Wahed and Thall (2013) as a basis for frequentist G-
estimation of mean survival time for the leukemia trial regimes. We will apply the Bayesian
nonparametric DDP-GP model to this basic structure to obtain posterior means and credible
intervals of mean survival time for each DTR.
Recall that the disease states are D = death, R = resistant disease, C = complete
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remission, and P = progressive disease. In stage ` = 1 (induction chemotherapy), the
three events D, R, and C are competing risks since only one can be observed. For the
ith patient, the stage 1 outcome is s1i = D if the patient dies, s1i = R if the patient’s
disease is resistant to induction, and s1i = C if induction achieves CR. The corresponding
transition times are T
(0,D)
i = time to D (the left most arrow in Figure 1), T
(0,R)
i = time to
R, and T
(0,C)
i = time to C. In stage 2, the transition time T
(R,D)
i is defined only if s1i = R,
T
(C,D)
i is defined only if s1i = C and s2i = D, and T
(C,P )
i is defined only if s1i = C and
s2i = P . The time from post-CR progression to death, T
(P,D)
i , is defined if s1i = C and
s2i = P . We thus define seven counterfactual transition times T
k
i , where k indexes the
transitions (0, D), (0, R), (0, C), (R,D), (C,D), (C,P ), (P,D). Figure 1 shows a flowchart of
the possible outcome pathways. A dynamic treatment regime for this data may be expressed
as Z = (Z1, Z2,1, Z2,2) where Z1 is the induction chemo, Z2,1 is the salvage therapy given if
s1i = R, and Z
2,2 is the salvage therapy given if s1i = C and s2i = P.
Our primary goal is to estimate mean survival time for each DTR (Z1, Z2,1, Z2,2) while
accounting for baseline covariates and non-random treatment assignment. Under the DDP-
GP model, we denote the mean survival time for a future patient under Z by
η(Z) = E(T | Z). (8)
The survival time for a future patient i = n+ 1 is
Ti = I(s1i = D)T
(0,D)
i + I(s1i = R)(T
(0,R)
i + T
(R,D)
i )
+ I(s1i = C){I(s2i = D)(T (0,C)i + T (C,D)i ) + I(s2i = P )(T (0,C)i + T (C,P )i + T (P,D)i )}. (9)
The expectation of (9) under the DDP-GP model is evaluated by applying the law of total
probability, using the same steps as in Wahed and Thall (2013). We first condition on
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the four possible cases, (s1i = D), (s1i = R), (s1i = C, s2i = D) and (s1i = C, s2i = P ),
compute the conditional expectation in each case, and then average across the cases. This
computation requires evaluating seven expressions for the conditional mean transition times
ηk(Z,xk) = E(T k | Z,xk)
under F k(· | xk), for each k. For example, η(P,D)(Z1, Z2,2,x0, T (0,C), T (C,P )) is the conditional
mean remaining survival time, from P to D, given that C was achieved in stage 1 with
frontline therapy Z1, followed by P and salvage therapy Z2,2 in stage 2. The DDP-GP models
for F k(· | xk), k = 1, . . . , nT = 7 define most of the marginalization for the expectation in
η(Z), leaving only conditioning on the baseline covariates x0i . As Wahed and Thall (2013),
we use the empirical distribution p̂(x0) over the observed patients to define an overall mean
survival time (8). The described evaluation of η(Z) is an application of Robins’s G-formula
(Robins, 1986; Robins et al., 2000). The complete expression is given as equation (14) in
the Appendix. In the upcoming discussion we will use η(Z) to evaluate and compare the
proposed approach.
6.2 Leukemia Data – Inference for the Survival Regression
To analyze the AML-MDS trial data under the proposed DDP-GP model, we first implement
posterior inference for six of the nT = 7 transition times. The exception is T
(C,D). Due to the
limited sample size – only 9 patients died after C without first suffering disease progression
(P ) – we do not implement the DDP-GP model, and instead use an intercept-only Weibull
AFT model. Table 1 summarizes the data. The table reports the number of patients and
median transition times for some selected transitions.
We first report results for T (R,D). Of 210 patients, 39 (18.57%) experienced resistance to
their induction therapies. The rate of resistance varied across regimes, from 31% for patients
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Resistance Die after resistance
Induction N TR(days) Salvage N TRD(days)
All 39 59 (47,84) All 37 76 (27,187)
FAI 17 63 (41,97) HDAC 25 65 (21,154)
FAI+ATRA 13 59 (55,76)
FAI+GCSF 4 77 (43.5,106.75) non HDAC 12 146 (79, 376.75)
FAI+ATRA+GCSF 5 51 (48, 65)
CR Die after progression
Induction N TC(days) Salvage N T PD(days)
All 102 32 (27,41) All 83 120 (45,280)
FAI 20 31 (29, 44) HDAC 47 106 (45,175.5)
FAI+ATRA 26 31 (25.25, 35)
FAI+GCSF 28 35.5 (28,42.75) non HDAC 36 147.5 (42.75, 592.25)
FAI+ATRA+GCSF 28 32 (26,41)
Table 1: The sample median of each transition time is given, with lower 25% quantile and
upper 75% quantile in the parenthesis next to each median .
receiving FAI, 24% for FAI plus ATRA, 7.8% for FAI plus GCSF, and 10% for FAI plus
ATRA plus GCSF. The times to treatment resistance were longer, with greater variability
in the FAI plus GCSF arm compared to the other three arms. Among the 39 patients who
were resistant to induction therapies, 27 were given HDAC as salvage treatment, of whom
2 were censored before observing death. Figure 6 summarizes survival regression under the
proposed DDP-GP model by plotting posterior predicted survival functions for a hypothetical
future patient at scaled age 0 with poor prognosis cytogenetic abnormality. The figure shows
posterior predicted survival functions, arranged by different induction therapies Z1 (the four
curves in each panel), T (0,R) and Z2,1 (as indicated in the subtitle). From Figure 6, we can
see that patients with shorter T (0,R) have lower predicted survival once their cancer became
resistant. Also, patients with s1 = R who received Z
2,1 = HDAC as salvage had worse
survival predication than patients who received salvage treatment with non HDAC. Similar
results can be obtained for other transition times. Inferences for similar survival regressions
for T (C,P ) and T (P,D) are summarized in the on-line supplement.
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Figure 6: Survival regression for T (R,D) in the AML-MDS trial. Panels (a)-(d) show the posterior
estimated survival functions for a future patient at scaled age 0 with poor prognosis cytogenetic
abnormality, with T (0,R) and Z2,1 as indicated. Survival curves are shown for four induction
therapies. Black, red, green and blue curves indicate Z1 = FAI, FAI+ATRA, FAI+GCSF and
FAI+ATRA+GCSF, respectively.
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Regime (A,B1, B2) Estimated mean OS times (days)
DDP-GP
IPTW Posterior mean 90% CI
(FAI, HDAC, HDAC) 191.67 390.35 (286.47 545.6)
(FAI, HDAC, other) 198.18 416.34 (295.84 581.73)
(FAI, other, HDAC) 216.59 394.2 (287.15 538.63)
(FAI, other, other) 222.42 420.19 (296.51 579.05)
(FAI+ATRA, HDAC, HDAC) 527.43 572.9 (416.63 829.12)
(FAI+ATRA, HDAC, other) 458.85 617.15 (434.4 905.82)
(FAI+ATRA, other, HDAC) 532.29 573.46 (413.59 830.39)
(FAI+ATRA, other, other) 464.39 617.71 (434.49 900.32)
(FAI+GCSF, HDAC, HDAC) 326.15 542.06 (393.49 725.23)
(FAI+GCSF, HDAC, other) 281.78 578.24 (419.69 781.05)
(FAI+GCSF, other, HDAC) 327.66 542.5 (392.77 726.08)
(FAI+GCSF, other, other) 283.36 578.68 (421.46 781.26)
(FAI+ATRA+GCSF, HDAC, HDAC) 337.44 458.34 (327.91 651.21)
(FAI+ATRA+GCSF, HDAC, other) 285.64 502.48 (360.29 727.44)
(FAI+ATRA+GCSF, other, HDAC) 362.56 459.42 (328.09 651.61)
(FAI+ATRA+GCSF, other, other) 309.62 503.56 (358.84 726.88)
Table 2: Mean overall survival time under the IPTW method and the posterior mean and
90% credible interval (CI) under the DDP-GP model.
6.3 Estimating the Regime Effects
In the AML-MDS trial, the four induction therapies and two salvage therapies define a total
16 regimes. The mean survival time estimates under each of the 16 regimes were calculated
using posterior inference under independent DDP-GP models F k(Y ki | xki ) for each of the
nT = 7 transition times. For comparison we also evaluated mean survival times under the
IPTW method. See equation (16) in the Appendix for details. Table 2 summarizes the results
under IPTW and under the DDP-GP model (including 90% credible intervals). Figure (7)
shows boxplots of the marginal posterior distributions of survival times under the DDP-GP
model for the same 16 regimes.
The two methods give very different estimates for mean survival time, with the DDP-GP
likelihood-based estimator larger than the corresponding IPTW estimator for most regimes.
The differences are expected because of the distinct properties of these two methods. The
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Figure 7: Marginal posterior distributions of overall survival time under the DDP-GP model
for all 16 regimes.
IPTW estimator uses the covariates to estimate the regime probability weights. In contrast,
the DDP-GP likelihood-based method computes mean survival time, using G-estimation,
accounting for patients’ covariates and previous transition times in addition to treatment
followed by marginalizing over the empirical covariate distribution to obtain η(Z). Addition-
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ally, the IPTW estimate is calculated from the overall samples, whereas the likelihood-based
DDP-GP method models each transition time distribution separately, which reduces the ef-
fective sample size for each model fit and thus increases the overall variability even though
they share the same prior for the βk’s.
Under both methods, the estimates were smallest for the four regimes with FAI as induc-
tion therapy regardless of salvage treatment, and the 90% credible intervals were relatively
small for these inferior regimes. Under the IPTW method, the estimates were largest for the
four regimes with FAI plus ATRA as induction therapy, and the best regime is (FAI+ATRA,
other, HDAC). With the DDP-GP likelihood-based approach, FAI plus ATRA as induction
also gave the largest estimates, except for the regimes (FAI+GCSF, HDAC, other) and
(FAI+GCSF, other, other), while the best regime is (FAI+ATRA, other, other). Most im-
portantly, the DDP-GP likelihood-based approach showed that (FAI + ATRA, Z2,1, other)
was superior to (FAI + ATRA, Z2,1, HDAC) regardless of Z2,1. Therefore, our results sug-
gest that (1) FAI plus ATRA was the best induction therapy, (2) if the patient’s disease was
resistant to FAI plus ATRA, then it was irrelevant whether the salvage therapy contained
HDAC, and (3) if patients experienced progression after achieving CR with FAI plus ATRA,
then salvage therapy with non HDAC was superior.
These conclusions, although not confirmatory, are contradictory with those given by
Estey et al. (1999), who concluded that none of the three adjuvant combinations FAI plus
ATRA, FAI plus GCSF, or FAI plus ATRA plus GCSF were significantly different from FAI
alone with respect to either survival or event-free survival time, based on consideration of
only the front-line therapies by applying conventional Cox regression and hypothesis testing.
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7 Conclusions
We have proposed a Bayesian nonparametric DDP-GP model for analyzing survival data and
evaluating joint effects of induction-salvage therapies in clinical trials, using the posterior
estimates, to predict survival for future patients. The Bayesian paradigm works very well,
and the simulation studies suggest that our DDP-GP method yields more reliable estimates
than IPTW.
We employed two different methods to evaluate the 16 possible two-stage regimes for
choosing induction and salvage therapies in the leukemia trial data. The IPTW method
estimates the regime effect by using covariates only to compute the assignment probabilities
of salvage therapies to correct for bias. In contrast, likelihood-based G-estimation under
the DDP-GP model accounts for all possible outcome paths, the transition times between
successive states, and effects of covariates and previous outcomes, on each transition time.
Although the two methods gave different numerical estimates of mean survival time, they
both reached the conclusion that FAI plus ATRA was the best induction therapy and FAI was
the worst induction therapy. Although our current models are set up for two-stage treatment
regimes, they easily can be extended to other applications with multi-stage regimes.
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Appendix
The following structure is that given by Wahed and Thall (2013), and is included here for
completeness. The risk sets of the seven transition time in the leukemia trial are defined as
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follows. Let G0 = {1, . . . , n} denote the initial risk set at the start of induction chemotherapy,
and G(0,r) = {i : s1i = r} for r = D,C,R, so G0 = G(0,D) ∪ G(0,C) ∪ G(0,R). Similarly,
G(C,P ) = {i : s1i = C, s2i = P} is the later risk set for T (P,D).
To record right censoring, let Ui denote the time from the start of induction to last
followup for patient i. We assume that Ui is conditionally independent of the transition
times given prior transition times and other covariates. Censoring of event times occurs by
competing risk and/or loss to follow up. For a patient i in the risk set for event time T ki ,
let δki = 1 if a patient i is not censored and 0 if patient i is right censored. For example,
δ
(0,D)
i = 1 for i ∈ G0 if T (0,D)i = min(Ui, T (0,k)i , k = D,C,R). Similarly, δ(R,D)i = 1 for
i ∈ G(0,R) if T (0,R)i +T (R,D)i < Ui and δ(P,D)i = 1 for i ∈ G(C,P ) if T (0,C)i +T (C,P )i +T (P,D)i < Ui.
Let Vx,i denote the observed time for patient i in risk set G
x, as follows. For i ∈ G0
let V1,i = min(T
(0,D)
i , T
(0,R)
i , T
(0,C)
i , Ui) denote the observed time for the stage 1 event or
censoring. For i ∈ G(0,C) let VCi = min(T (C,D)i , T (C,P )i , Ui− T (0,C)i ) denote the observed event
time for the competing risks D and P and loss to followup. Similarly, for i ∈ G(0,R), let VRi =
min(T
(R,D)
i , Ui − T (R,D)i ), and for i ∈ G(C,P ) let V(C,P ),i = min(T (P,D)i , Ui − T (0,C)i − T (C,P )i ).
The joint likelihood function is the product L = L1L2L3L4. The first factor L1 corre-
sponds to response to induction therapy,
L1 =
∏
i∈G0
∏
k∈{D,R,C}
f (0,k)(V1,i | xki )δ
(0,k)
i S(0,k)(V1,i | xki )1−δ
(0,k)
i . (10)
where Sk = 1− F k. The second factor L2 corresponds to patients i ∈ G(0,R) who experience
resistance to induction and receive salvage Z2,1,
L2 =
∏
i∈G(0,R)
f (R,D)(VRi | x(R,D)i )δ
(R,D)
i S(R,D)(VRi | x(R,D)i )1−δ
(R,D)
i . (11)
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The third factor L3 is the likelihood contribution from patients achieving CR,
L3 =
∏
i∈G(0,C)
∏
k=(C,D),(C,P )
fk(VCi | xki )δ
k
i Sk(VCi | xki )1−δ
k
i . (12)
The fourth factor L4 is the contribution from patients who experience tumor progression
after CR
L4 =
∏
i∈G(C,P )
f (P,D)(VCP,i | x(P,D)i )δ
(P,D)
i S(P,D)(VCP,i | x(P,D)i )1−δ
(P,D)
i . (13)
The mean survival time of a patient treated with regime Z = (Z1, Z2,1, Z2,2) is
η(Z) =
∫ [
p(s1 = D | x0, Z1)η(0,D)(x0, Z1)
]
dp̂(x0)
+
∫ {
p(s1 = R | x0, Z1)
[
ηR(x0, Z1) +
∫
η(R,D)(x0, Z1, Z2,1, T (0,R))dµ(T (0,R))
]}
dp̂(x0)
+
∫
p(s1 = C | x0, Z1)
[
ηC(x0, Z1) +
∫ [
p(s2 = D | s1 = C,x0, Z1, T (0,C))η(C,D)(x0, Z1, TC)
+ p(s2 = P | s1 = C,x0, Z1, T (0,C))[η(C,P )(x0, Z1, T (0,C))
+
∫
η(P,D)(x0, Z1, Z2,2T (0,C), T (C,P ))dµ(T (C,P ))]dµ(T (0,C))
]
dp̂(x0). (14)
We compute the IPTW estimates for overall mean survival with regime Z as
IPTW (Z) =
n∑
i=1
wi(Z)Ti /
n∑
i=1
wi(Z), (15)
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where
wi(Z) =
I(Z = Zi)δi
Kˆ(Ui)
[
I(s1i = D) + I(s1i = R)Ii(Z
2,1)/Pˆr(Z2,1 | s1i = R,Z1,x0i , T (0,R)i )
+I(s1i = C, s2i = D)
+I(s1i = C, s2i = P )Ii(Z
2,2)/Pˆr(Z2,2 | s1i = C, s2i = P,Z1,x0i , T (0,C)i , T (C,P )i )
]
.
(16)
In (16), Kˆ is the Kaplan-Meier estimator of the censoring survival distribution K(u) =
P (U ≥ t) at time t. Ii(Z) is is an indictor of treatment Z and 0 otherwise, and Pˆr(Z2,1 |
s1i = C,Z
1,x0i , T
(0,R)
i ) is the probability of receiving salvage treatment Z
2,1 estimated using
logistic regression, and similarly for Pˆr(Z2,2 | s1i = C, s2i = P,Z1,x0i , T (0,C)i , T (C,P )i ). The
above estimator has been shown to be consistent under suitable assumptions (Wahed and
Thall, 2013; Scharfstein et al., 1999).
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